股骨强度无创评估在髋部骨折风险评价中的观点
本文综述了实验与临床证据,评估双能X线吸收法测得的面积骨密度(aBMD)和/或有限元分析(FEA)估算的股骨强度是否反映股骨近端实际强度,并与髋部骨折风险及治疗变化相关。结论认为aBMD和估算股骨强度是良好的骨折风险预测指标,可能作为临床试验的替代终点,FEA尚需进一步改进。
要点
- aBMD和CT-FEA估算的股骨强度可解释大部分离体股骨强度并预测在体髋部骨折风险。
- 股骨aBMD变化与骨质疏松治疗抗骨折疗效强相关,FEA的同类数据目前不可用。
- 髋部aBMD和估算股骨强度可能作为临床试验的骨折替代终点。
核心结论
- 髋部aBMD和估算的股骨强度是良好的骨折风险预测指标,可能作为临床试验的替代终点。
研究设计与样本
- 本文为综述,回顾了关于aBMD和/或CT-FEA估算股骨强度与髋部骨折风险及其治疗变化关联的实验与临床证据。
主要发现
- CT-FEA估算的股骨强度可解释大部分离体股骨强度,并在在体预测髋部骨折风险。
- 股骨aBMD变化与骨质疏松治疗的抗骨折疗效强相关,但FEA的 comparable 数据目前不可用。
临床怎么用
- 临床可依据髋部aBMD和估算股骨强度预测髋部骨折风险。
- 股骨aBMD变化可用于监测骨质疏松治疗的抗骨折效果。
局限性
- FEA的改进可能需要纳入骨小梁方向、增强的皮质骨建模、衰老对骨组织延展性的影响以及多种侧向跌倒加载条件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We reviewed the experimental and clinical evidence that hip bone strength estimated by BMD and/or finite element analysis (FEA) reflects the actual strength of the proximal femur and is associated with hip fracture risk and its changes upon treatment. INTRODUCTION: The risk of hip fractures increases exponentially with age due to a progressive loss of bone mass, deterioration of bone structure, and increased incidence of falls. Areal bone mineral density (aBMD), measured by dual-energy X-ray absorptiometry (DXA), is the most used surrogate marker of bone strength. However, age-related declines in bone strength exceed those of aBMD, and the majority of fractures occur in those who are not identified as osteoporotic by BMD testing. With hip fracture incidence increasing worldwide, the development of accurate methods to estimate bone strength in vivo would be very useful to predict the risk of hip fracture and to monitor the effects of osteoporosis therapies. METHODS: We reviewed experimental and clinical evidence regarding the association between aBMD and/orCT-finite element analysis (FEA) estimated femoral strength and hip fracture risk as well as their changes with treatment. RESULTS: Femoral aBMD and bone strength estimates by CT-FEA explain a large proportion of femoral strength ex vivo and predict hip fracture risk in vivo. Changes in femoral aBMD are strongly associated with anti-fracture efficacy of osteoporosis treatments, though comparable data for FEA are currently not available. CONCLUSIONS: Hip aBMD and estimated femoral strength are good predictors of fracture risk and could potentially be used as surrogate endpoints for fracture in clinical trials. Further improvements of FEA may be achieved by incorporating trabecular orientations, enhanced cortical modeling, effects of aging on bone tissue ductility, and multiple sideway fall loading conditions.
引用
- Bouxsein ML, Zysset P, Glüer CC, et al. Perspectives on the non-invasive evaluation of femoral strength in the assessment of hip fracture risk. Osteoporos Int. 2020. PMID: 31900541. doi:10.1007/s00198-019-05195-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。